The Celiac Disease Foundation is committed to representing the celiac disease patient voice in policy and healthcare reform, and can better do so alongside strong allies with common goals. To this end, on March 20, 2018, Alana Broe, Legislative Analyst for the Celiac Disease Foundation, attended the National Coalition of Autoimmune Patient Groups (NCAPG) meeting. […]
Accelerating diagnosis, treatments, and a cure for celiac disease and non-celiac gluten sensitivity through research, education, and advocacy.
As part of the Celiac Disease Foundation’s expanding effort to give voice to the celiac disease community in important areas of healthcare policy and federal funding for disease research, Laura Boone, Celiac Disease Foundation Development Manager and Alana Broe, Celiac Disease Foundation Legislative Analyst, attended the Digestive Disease National Coalition (DDNC) Public Policy Forum held […]
In recent years, there has been a marked increase in the number of people diagnosed with celiac disease around the world. This pattern suggests that a greater percentage of the population is afflicted than was previously believed. Meanwhile, the rate of child mortality has been decreasing. This is particularly obvious in developing countries where mortality […]
Currently, the only effective treatment for celiac disease is a strict, gluten-free diet for life. Studies have shown that patients who take their diet very seriously not only reduce their risk of long-term health complications, including cancers and bone deterioration, but also tend to be free from stomach and intestinal discomfort. We know that there […]
In an effort to give voice to the celiac disease community in important areas of healthcare reform, on February 15, 2018, Alana Broe, the Celiac Disease Foundation’s Legislative Analyst, attended the National Health Council (NHC) Conference: Ensuring the Patient Voice in Quality. This educational program connected patients, disease advocacy organizations, and quality measuring organizations to […]
On December 12, 2017, the Food & Drug Administration (FDA) issued guidance to drug manufacturers to voluntarily label medications that do not contain gluten with the following statement: “Contains no ingredient made from a gluten-containing grain (wheat, barley, or rye).” The FDA granted a 60 day period to submit comments and suggestions regarding this draft […]